ABBV - AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered
By Jonathan Weber
Pharmaceutical giant AbbVie Inc. (ABBV) has been one of our top-ranked dividend stocks for an extended period. We have written previously about our three pillars of expected returns, and AbbVie is attractive across the three pillars. The stock is undervalued, the company has future earnings growth potential, and it offers a high dividend yield.
AbbVie is also a dividend growth stock. Going back to its days as a subsidiary of Abbott, AbbVie is a Dividend Aristocrat with over 30 consecutive years of dividend increases. You can see all 57